Tag: Idose tr

According to the Glaucoma Research Foundation, glaucoma is the leading cause of irreversible blindness, affecting millions of people worldwide. Recent FDA approvals for iDose TR and Omlonti represent significant advancements in the treatment landscape, offering new mechanisms to control intraocular pressure (IOP) and improve patient quality of life. These two new drugs for glaucoma present innovative alternatives to traditional eye drops.

With an estimated 76 million people affected worldwide, innovation in glaucoma treatment is crucial to prevent vision loss. For patients and clinicians seeking the latest options, a key question is: what is the newest drug for glaucoma? The answer lies not only in new eye drops but in advanced, sustained-release delivery systems like the iDose TR implant.